Can stem cell therapy help with cartilage damage? Honest evidence review, candidate criteria, realistic outcomes, and what remains unproven.
Stem cell therapy for cartilage damage is one of the most actively researched areas in regenerative orthopaedics. Mesenchymal stem cells (MSCs) — particularly those derived from umbilical cord tissue — have shown the ability to reduce joint inflammation, support the surrounding tissue environment, and in some cases contribute to partial filling of cartilage defects. But this is not the same as growing back cartilage that has fully worn away. The distinction matters enormously, and any honest conversation about this treatment has to start there.
Cartilage is avascular — it has no blood supply of its own. That is the core problem. Most healing in the human body depends on blood flow bringing repair cells and nutrients to damaged tissue. Cartilage cannot do that. When it breaks down, whether gradually through osteoarthritis or acutely through injury, the body's natural repair mechanisms are limited. Fibrocartilage — the inferior repair tissue the body does sometimes produce — is structurally weaker than the hyaline cartilage it replaces. It wears down faster. It does not absorb load the same way.
Mesenchymal stem cells do not simply arrive in a joint and transform into chondrocytes (cartilage cells). The biology is more subtle — and more interesting — than that. The primary mechanism appears to be paracrine signalling: the chemical messages MSCs send to their local environment. When introduced into or near a damaged joint, MSCs release a range of bioactive molecules including transforming growth factor-beta (TGF-β), fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), and various anti-inflammatory cytokines.
The honest answer: the evidence for MSC therapy in cartilage and joint conditions is among the strongest within regenerative medicine — but it is still not at the level of large-scale phase III trials with long-term follow-up across all cartilage conditions. Here is what the clinical literature does and does not show.
This is where the evidence base is deepest. Multiple randomised controlled trials and systematic reviews have examined intra-articular MSC injection for knee osteoarthritis. A 2021 systematic review published in a peer-reviewed rheumatology journal analysed data from over 1,000 patients across 30 studies and found statistically significant improvements in pain scores (VAS and WOMAC) and functional outcomes at 6 and 12 months compared to baseline. Importantly, a subset of trials using MRI follow-up reported measurable increases in cartilage volume in some patients — though this finding was not universal and response varied considerably.
Localised chondral defects — the kind caused by sports injuries or acute trauma in younger patients — have also been studied, typically using MSC-seeded scaffolds or direct injection. Early-phase trials report promising defect filling on MRI at 12–24 months, with functional improvements in pain and joint loading. But sample sizes are small, and longer follow-up data beyond 3–5 years is limited for this specific application.
Evidence for hip and shoulder cartilage is less mature than for the knee. Case series and small trials suggest similar anti-inflammatory and symptomatic benefits, but the anatomy of these joints makes intra-articular delivery more technically demanding and the patient populations studied are smaller. More research is underway.
Transparency matters here. There are several things the current evidence does not support — and a reputable clinic should say so clearly.
Candidacy for MSC therapy in cartilage conditions requires a detailed individual clinical assessment. That said, the research literature points fairly consistently toward the profiles most likely to benefit.
If you are considering treatment, here is what the process actually looks like — from first contact through to follow-up.
The cells used in our clinic are allogeneic umbilical cord-derived MSCs — donated from ethically screened, consented donors following healthy full-term births. Cord-derived MSCs are particularly well-studied for their low immunogenicity (meaning the recipient's immune system is unlikely to reject them), their potent anti-inflammatory signalling profile, and their consistent quality across batches compared to autologous (patient's own) cell harvesting.
Non-Turkish international patients are treated under the clinic's international patient protocol within the TİTCK regulatory framework — no individual Ministry of Health permit is required per patient. Turkish citizens, however, do require individual Sağlık Bakanlığı (Ministry of Health) approval for cell therapy treatment. This distinction is important and worth understanding before you travel.
Most patients who respond to MSC therapy for cartilage conditions notice changes gradually — not immediately. The typical response curve runs over 3–6 months, with some patients continuing to improve for up to 12 months post-treatment. What does 'improvement' tend to mean in practice?
MSC therapy delivered by intra-articular injection carries a different risk profile than systemic intravenous infusion. Local side effects are most commonly reported and include temporary joint swelling, mild increased pain for 24–72 hours post-injection (a recognised inflammatory response as the tissue responds to the cells), and in rare cases, localised discomfort at the injection site. These typically resolve within a few days.
Most international patients visiting our Istanbul clinic for cartilage-related MSC therapy plan a stay of 3–5 days. The treatment itself is a single outpatient session, but we recommend arriving a day before for the full clinical assessment, and remaining one additional day for post-procedure monitoring and personalised rehabilitation guidance.
MSC-based therapy for cartilage conditions is classified as investigational in most regulatory jurisdictions — including the FDA (US), MHRA (UK), and TGA (Australia) — meaning it is not routinely reimbursed as standard care and is still the subject of ongoing clinical trials. In Turkey, treatment is provided within the TİTCK-regulated framework under the clinic's established protocols. This is a legal, physician-supervised medical framework — not a grey-market offer. Patients should understand that receiving treatment abroad under a different jurisdiction's framework does not change how that treatment is classified in their home country.
For most cartilage conditions, an initial protocol of one to two intra-articular sessions is evaluated first, with response assessed at three to six months before any further sessions are discussed. Some patients with bilateral joint involvement or significant disease burden may be recommended a multi-session approach from the outset, but this is always determined individually. There is no universal protocol — your case is reviewed on its own merits.
For some patients with moderate osteoarthritis, MSC therapy may contribute to a meaningful delay in symptom progression — buying time before a surgical decision becomes necessary. Several clinical trials have reported that a proportion of patients who received MSC injection did not require escalation to surgery within the follow-up period. But no trial has demonstrated that MSC therapy permanently prevents joint replacement across all patients, and for those with end-stage disease, the structural damage is already beyond what regenerative approaches can meaningfully address.
Platelet-rich plasma (PRP) and MSC therapy are both regenerative approaches, but they work through different mechanisms. PRP concentrates growth factors from the patient's own blood and has a shorter duration of effect in most studies. MSC therapy introduces living cells capable of sustained paracrine signalling over weeks to months, and the anti-inflammatory capacity of MSCs — particularly cord-derived MSCs — is generally more potent than PRP alone. For mild symptoms, PRP may be a reasonable starting point. For moderate-to-severe osteoarthritis, the evidence increasingly supports MSC therapy as the stronger option.
The honest answer is: no one knows for certain, and 'permanent' is not a realistic frame for any joint treatment in a condition that is fundamentally degenerative. Most trial data suggests meaningful benefit lasting 12–24 months in responders. Some patients report sustained improvement beyond that period; others plateau or decline and benefit from a repeat session. Ongoing maintenance of joint health — through weight management, appropriate exercise, and rehabilitation — appears to influence durability of benefit significantly.
Bring your most recent MRI or X-ray of the affected joint (within the past 12–18 months is ideal), a list of current medications, any previous injection records (steroid, hyaluronic acid, PRP), a summary of surgical history if relevant, and any physiotherapy or rehabilitation reports. The more complete your clinical picture, the more accurate our pre-treatment assessment will be — and the clearer we can be with you about whether treatment is likely to be appropriate.
Stem Cell Therapy for Cartilage Damage: What the Evidence Actually Shows in 2026